Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 17, 2025

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma

Published on: June 6, 2025

GP100 expression is variable in intensity in melanoma.

Jacqueline E Mann¹, Nitzan Hasson¹, David G Su²

¹Division of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA.

Cancer Immunology, Immunotherapy : CII

|August 6, 2024

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Diagnosis of granulomatous inflammation in thoracic small biopsies and fine needle aspiration specimens: a multi-institutional study.

Journal of the American Society of Cytopathology·2026

Same author

Development of [<sup>111</sup>In]In-CHX-A″-DTPA-αCD68 for ImmunoSPECT to Image Murine Macrophages.

Molecular pharmaceutics·2026

Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026

Same author

Advances in Cancer Immunotherapy for Solid Tumors.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Clinicopathologic characterization of renal tumors with Folliculin (FLCN) biallelic inactivation.

Virchows Archiv : an international journal of pathology·2026

Same author

Leading Consortiums from the Ground Up: Leveraging Trainee Collaboration to Create Consensus Guidelines.

Annals of surgical oncology·2026

Same journal

Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII·2026

Same journal

Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.

Cancer immunology, immunotherapy : CII·2026

Same journal

Time-dependent cytokine landscapes in an ex vivo microfluidic glioblastoma platform.

Cancer immunology, immunotherapy : CII·2026

Same journal

Correction: Repurposing public sarcoma multi-omics for neoantigen discovery.

Cancer immunology, immunotherapy : CII·2026

Same journal

A low-dose self-amplifying mRNA vaccine encoding HPV16 E6/E7 induces potent T-cell immunity and antitumor protection in mice.

Cancer immunology, immunotherapy : CII·2026

Same journal

GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation.

Cancer immunology, immunotherapy : CII·2026

See all related articles

This summary is machine-generated.

gp100 expression is higher in metastatic melanoma, but intensity varies. This finding is crucial for selecting patients for gp100-targeted therapies like Tebentafusp in cutaneous melanoma clinical trials.

Area of Science:

Oncology
Immunology
Dermatology

Background:

gp100 is a target for melanoma therapies due to its specificity in melanocytes.
Tebentafusp, a gp100-targeting bispecific antibody, shows promise in uveal melanoma and is being studied in cutaneous melanoma.
Limited data exists on gp100 expression levels in advanced cutaneous melanoma.

Purpose of the Study:

To investigate the extent and intensity of gp100 expression in a large cohort of primary and metastatic melanomas.
To assess the variability of gp100 expression in different melanoma stages.
To inform patient selection for gp100-directed therapies.

Main Methods:

Immunohistochemistry (IHC) was used to evaluate gp100 expression in primary and metastatic melanoma samples.

Keywords:

Glycoprotein 100 ImmTAC Melanoma Targeted therapy Tebentafusp

More Related Videos

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

Experimental Metastasis Assay

Experimental Metastasis Assay

Published on: August 24, 2010

Related Experiment Videos

Last Updated: Jun 17, 2025

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma

DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma

Published on: June 6, 2025

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

Experimental Metastasis Assay

Experimental Metastasis Assay

Published on: August 24, 2010

Quantitative immunofluorescence was employed to confirm and quantify gp100 expression variability.

Analysis of a large patient cohort provided comprehensive data on gp100 expression patterns.

Main Results:

gp100 expression was globally higher in metastatic melanoma samples compared to primary.
gp100 expression was almost uniformly positive in metastatic melanomas, but with variable intensity.
Quantitative immunofluorescence confirmed significant variability in gp100 expression levels.

Conclusions:

gp100 is widely expressed in metastatic melanoma, though expression intensity varies.
Understanding gp100 expression levels is critical for optimizing patient selection in clinical trials.
Further studies correlating drug activity with gp100 expression levels are warranted to enhance therapeutic efficacy.